"The FDA's Fast Track designation is an important recognition of our ADVM-022 gene therapy program," said Leone Patterson, interim president and chief executive officer of Adverum Biotechnologies. "We look forward to working with the FDA and benefiting from the potential expedited development and regulatory path offered by their Fast Track program."